MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Meloxicam/rizatriptan (Primary) ; Meloxicam; Rizatriptan
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms MOMENTUM
- Sponsors Axsome Therapeutics
- 12 Nov 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2019.
- 07 Nov 2019 According to an Axsome Therapeutics media release, top-line results of this study are expected in 4Q 2019.
- 07 Nov 2019 Status changed from recruiting to active, no longer recruiting as per the Axsome Therapeutics media release.